Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its drug Anaphylm. The FDA identified deficiencies in Aquestive's New Drug Application, causing a 37% stock price drop. The firm is examining possible wrongdoing by company directors and officers. Shareholders may have legal options and are encouraged to contact the law firm for more information.
Aquestive Therapeutics saw a 37% stock drop amid an investigation into possible false statements about FDA approval prospects. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 20:05 WIB: out of 100 priced US health stocks, 46 rose and 50 fell. Notable movers include Danaher Corporation (DHR) at USD 220.01 with a 1-day change of +2.06%, AbCellera Biologics Inc (ABCL) at USD 12.88 with -2.05%, and Novavax Inc (NVAX) at USD 11.09 with -2.03%.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
